Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biocon Limited
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TREGO-DM2-03-I-01 | P3 |
Completed |
Type 2 Diabetes |
2019-02-06 |